Gore's Cardioform ASD Occluder Approved by FDA
June 4, 2019—Gore & Associates announced FDA premarket approval of the company's Cardioform atrial septal defect (ASD) occluder for percutaneous closure of ostium secundum ASDs.
Gore stated that the device features an anatomically adaptable waist that conforms to the defect to close ASDs with diameters of 8 to 35 mm, including those without a retroaortic rim, by facilitating optimal tissue ingrowth while maintaining thromboresistance.
According to the company, FDA approval was supported by data collected from the pivotal stage of the ASSURED clinical study, which demonstrated 100% closure success at 6 months in patients who underwent successful implantation.
The pivotal study evaluated the safety and efficacy of ASD closure using the Cardioform ASD occluder in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. The study included patients who were 2 to 84 years old across 22 investigation sites, including 15 children’s hospitals. The pivotal study met its safety, closure, and technical success primary endpoints.
In Gore's press release, the Coprincipal Investigator of the ASSURED study, Matthew J. Gillespie, MD, commented, “The FDA approval of the Gore Cardioform ASD occluder is a significant milestone for innovation in the minimally invasive treatment of ASDs. This soft, conformable device was not previously available for this range of defects but is now an option for larger defects that typically have a greater risk for complications, including right heart enlargement, atrial fibrillation, and pulmonary hypertension. The ability to retrieve and reposition the Gore Cardioform ASD occluder helps me ensure proper positioning and offers me confident closure.” Dr. Gillespie is a cardiologist at the Children’s Hospital of Philadelphia in Philadelphia, Pennsylvania.
Gore noted that in addition to the Cardioform ASD occluder, the company's occluder portfolio includes the Cardioform septal occluder, which is indicated for ASD closure for defects up to 17 mm and received FDA approval in April 2018 for patent foramen ovale closure to prevent recurrent ischemic stroke.
advertisement
Featured Video
Conquer the Calcium.
Deliver the Stent.
Sponsored by Cardiovascular Systems Inc.
Related Articles
Top 5 Articles From April 2019
TAVI: Which Valve for Which Patient?
A review of the technical challenges and optimal valve choices in different clinical and anatomic scenarios.
By Noman Ali, PhD; and Daniel J. Blackman, MD
Permanent Pacemaker Implantation After TAVR
Reviewing the current landscape of permanent pacemaker implantation post-TAVR and a look at the road ahead.
By Rahul Sharma, MD; and Rahul P. Sharma, MD
Bioprosthetic Valve Fracture During ViV TAVR
A step-by-step practical guide for performing BVF to facilitate ViV TAVR.
By Ahmed Almomani, MD; and Adnan K. Chhatriwalla, MD
Roundtable Discussion: TAVR in Low-Risk Patients
Experts discuss the significance of recent data and the potential impact on their practice.
With Kentaro Hayashida, MD, PhD, FESC, FACC, FJCS; Robert Ostfeld, MD, MSc, FACC; Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC; Michael J. Reardon, MD; and Steven J. Yakubov, MD, FACC, FSCAI
Simultaneous Measurement of Differential Pressures With a Dual Lumen Catheter
Using a dual lumen catheter to accurately measure pressures between two sites across a valve or stenosis.
By Christian Bradaric, MD
Top 5 from EVToday's Current Issue
What’s New in Y-90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Transradial Access for Hepatic Oncologic Interventions
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Contemporary Management of Pancreatic Cancer
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Top Tips in Interventional Oncology
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
